Seegene, a molecular diagnostic (MoDx) company based in Korea, has developed a real time “multiplex quantification” chemistry technology. Seegene’s new technology enables a real-time PCR-based detection and quantification of up to 20 analytes from a single sample and in a single tube utilizing existing multiplex capable thermal cyclers.

Seoul, KOREA ¶ Jun 01, 2012 (Whowired) -- Seegene, a molecular diagnostic (MoDx) company based in Korea, said on May 31 that it has developed a real time “multiplex quantification” chemistry technology. Seegene’s new technology enables a real-time PCR-based detection and quantification of up to 20 analytes from a single sample and in a single tube utilizing existing multiplex capable thermal cyclers.

Seegene expects its newly developed real-time multiplex quantification technology will be used as a crucial technology in tracking patient conditions for initial infections or managing medication treatment and after-treatment. Seegene’s CEO Chun Jong-yoon said “We expect the newly developed multiplex quantification technology will be widely applied to many different medical areas through our strategic partnerships with experts in diagnostic medicine and medical devices”.

  
At the 2012 American Association for Clinical Chemistry which will be held in Los Angeles this July, Seegene plans to unveil its multiplex quantification products based on the new technology designed to diagnose virus causing cervical cancer.

Adrian Han (press@whowired.com)